1
|
Bouzeid M, Clarenne J, Mongaret C, Pluchart H, Chanoine S, Vermorel C, Bosson JL, Bedouch P, Conort O, Gravoulet J, Janoly-Dumenil A, Juste M, Mongaret C, Bosson JL, Bedouch P. Using national data to describe characteristics and determine acceptance factors of pharmacists' interventions: a six-year longitudinal study. Int J Clin Pharm 2022; 45:430-441. [PMID: 36566276 DOI: 10.1007/s11096-022-01526-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Accepted: 11/30/2022] [Indexed: 12/25/2022]
Abstract
BACKGROUND In France, hospital pharmacists perform medication order reviews during patients' hospital stays. This activity can be centralized in the pharmacy or carried out directly in the ward, in collaboration with the healthcare team. During this review, pharmacists can make recommendations to optimize therapeutics. Since 2006, they can document their interventions, via the national Act-IP© observatory. AIM To determine the characteristics of pharmacists' interventions and their acceptance by physicians in French hospitals. METHOD A 6-year observational study of pharmacists' interventions documented on the Act-IP© French observatory between 2009 and 2014 was performed. Multiple logistic regression was undertaken to determine the predictors of physicians' acceptance of interventions. RESULTS A total of 194,684 pharmacists' interventions were documented and concerned mainly "dosage adjustment" (25.6%). These interventions were mostly related to drugs from the central nervous system (23.7%). Seventy percent of pharmacists' interventions were accepted by physicians. Acceptance rate was higher when conducted by a pharmacist regularly practicing in the ward (ORa = 1.60, CI 95 [1.57-1.64]). Physicians' acceptance was significantly associated with (1) ward specialty: emergency (ORa = 1.24, CI 95 [1.14-1.35]); (2) type of intervention: "drug discontinuation", "drug switch" (ORa = 1.15, CI 95 [1.12-1.19]) and "addition of a new drug" (ORa = 1.15, CI 95 [1.12-1.19]); (3) drug group: antineoplastic and immunomodulators (ORa = 3.67, CI 95 [3.44-3.92]). CONCLUSION This 6-year longitudinal study highlights the role of clinical pharmacists, and particularly the impact of those integrated into wards. This was found to improve intervention acceptance, potentially through collaboration with physicians in pursuit of patient care and drug safety.
Collapse
Affiliation(s)
- Mayssam Bouzeid
- CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, Univ. Grenoble Alpes, 38000, Grenoble, France
| | - Justine Clarenne
- BIOS EA 4691, Université de Reims Champagne-Ardenne, 51100, Reims, France.,Pharmacy Department, CHU Reims, 51100, Reims, France
| | - Céline Mongaret
- BIOS EA 4691, Université de Reims Champagne-Ardenne, 51100, Reims, France.,Pharmacy Department, CHU Reims, 51100, Reims, France
| | - Hélène Pluchart
- CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, Univ. Grenoble Alpes, 38000, Grenoble, France.,Pharmacy Department, Grenoble-Alpes University Hospital, 38000, Grenoble, France
| | - Sébastien Chanoine
- CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, Univ. Grenoble Alpes, 38000, Grenoble, France.,Pharmacy Department, Grenoble-Alpes University Hospital, 38000, Grenoble, France
| | - Céline Vermorel
- CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, Univ. Grenoble Alpes, 38000, Grenoble, France
| | | | - Jean-Luc Bosson
- CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, Univ. Grenoble Alpes, 38000, Grenoble, France
| | - Pierrick Bedouch
- CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, Univ. Grenoble Alpes, 38000, Grenoble, France. .,Pharmacy Department, Grenoble-Alpes University Hospital, 38000, Grenoble, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
de Juan-Roldán JI, Gavilán-Moral E, Leiva-Fernández F, García-Ruiz AJ. [Validation into Spanish of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire to assess patients' attitudes towards deprescribing. Research protocol]. Rev Esp Geriatr Gerontol 2021; 56:218-224. [PMID: 33892991 DOI: 10.1016/j.regg.2021.02.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 07/15/2020] [Accepted: 02/26/2021] [Indexed: 12/21/2022]
Abstract
INTRODUCTION AND OBJECTIVE Polypharmacy has become a priority public health problem in developed countries. In response to its approach, deprescription stands out. Its success will depend largely on the attitudes and beliefs of patients towards the number of drugs they are taking and their willingness to initiate a process of deprescription. To explore these factors, researchers have developed the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire, originally in English. The objective of this study is the validation into Spanish of rPATD questionnaire, both older adults and caregivers versions. MATERIAL AND METHODS A first qualitative validation phase and a second phase of analysis of its psychometric characteristics will be carried out through an observational descriptive study of validation of a measurement instrument. One hundred and twenty subjects (polymedicated older adults and caregivers) from three health centers will be selected by consecutive sampling. The questionnaire will be provided and clinical and sociodemographic data will be collected. Feasibility, reliability (through internal consistency and intraobserver reliability) and validity (apparent, construct and criterion) of the questionnaire will be evaluated. EXPECTED RESULTS It is expected to obtain a questionnaire that will serve as a tool for the clinician to identify patients with a favorable predisposition to deprescription and that will allow to contribute the patient's perspective to this process. CONCLUSION The use of the rPATD questionnaire, alone or integrated into other more complex interventions, may lead to an improvement in the quality of care for the polymedicated patients.
Collapse
Affiliation(s)
- José Ignacio de Juan-Roldán
- Departamento de Farmacología y Pediatría, Facultad de Medicina, Universidad de Málaga, Málaga, España; Laboratorio de Prácticas Innovadoras en Polimedicación y Salud, Cáceres, España.
| | - Enrique Gavilán-Moral
- Laboratorio de Prácticas Innovadoras en Polimedicación y Salud, Cáceres, España; Consultorio Rural Mirabel, Cáceres, España
| | - Francisca Leiva-Fernández
- Unidad Docente Multiprofesional de Atención Familiar y Comunitaria de Distrito de Atención Primaria Málaga/Guadalhorce, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA), REDISSEC ISCIII, Universidad de Málaga, Málaga, España
| | - Antonio J García-Ruiz
- Departamento de Farmacología y Pediatría, Facultad de Medicina, Universidad de Málaga, Málaga, España
| |
Collapse
|
3
|
Vivas-Consuelo D, Usó-Talamantes R, Trillo-Mata JL, Mendez-Valera P. Methods to control the pharmaceutical cost impact of chronic conditions in the elderly. Expert Rev Pharmacoecon Outcomes Res 2015; 15:425-37. [DOI: 10.1586/14737167.2015.1017564] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- David Vivas-Consuelo
- 1Research Centre for Health Economics and Management, Universitat Politècnica de València, Edificio7J, Campus de Vera s/n 46022-Valencia, Spain
| | - Ruth Usó-Talamantes
- 2Valencian Health Department (Conselleria de Sanitat), General Directorate of Pharmacy and Pharmaceutical Products, Valencia, Spain
| | - José Luis Trillo-Mata
- 2Valencian Health Department (Conselleria de Sanitat), General Directorate of Pharmacy and Pharmaceutical Products, Valencia, Spain
| | - Pablo Mendez-Valera
- 2Valencian Health Department (Conselleria de Sanitat), General Directorate of Pharmacy and Pharmaceutical Products, Valencia, Spain
| |
Collapse
|
5
|
Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother 2011; 45:977-89. [PMID: 21693697 DOI: 10.1345/aph.1p627] [Citation(s) in RCA: 165] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVE Most medications are prescribed, dispensed, and administered in ambulatory care settings, yet little information exists on the adverse effects of drugs in this setting. This review was conducted to estimate the prevalence of adverse drug events (ADEs) and the proportion of preventable ADEs in ambulatory care settings; compare data for different age groups including children, adults, and elderly patients; and review drug classes most commonly associated with ADEs. DATA SOURCES Four electronic databases-PubMed (1966-March 2011), International Pharmaceutical Abstracts (1970-March 2011), EMBASE (1980-March 2011), and the Cochrane Database of Systematic Reviews (1993-March 2011)-were systematically searched for published data. Bibliographies of retrieved articles were searched individually for additional relevant studies. STUDY SELECTION A standardized definition of an ADE was used to select studies in populations living in the community, with medical visits to primary care facilities, nonspecialty ambulatory care facilities, and/or admissions to a hospital for medication-related adverse events. DATA EXTRACTION Data were extracted using a standardized table. Forty-three studies met our inclusion criteria. DATA SYNTHESIS The median ADE prevalence rate for retrospective studies was 3.3% (interquartile range [IQR] 2.3-7.1%) vs 9.65% (IQR 3.3-17.35%) for prospective studies. Median preventable ADE rates in ambulatory care-based studies were 16.5%, and 52.9% for hospital-based studies. Median prevalence rates by age group ranged from 2.45% for children to 5.27% for adults, 16.1% for elderly patients, and 3.45% for studies including all ages. CONCLUSIONS Despite a recent increase in publications on ADEs in the ambulatory care setting, most studies remain hospital based. Notable differences in prevalence rates by age groups and by responsible drug categories provide guidance on how to direct attention toward effective targets for improvement of medication safety in ambulatory care settings.
Collapse
Affiliation(s)
- Stephanie V Taché
- Department of Family and Preventive Medicine, Paracelsus Medical University, Salzburg, Austria.
| | | | | |
Collapse
|